{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:29:31Z","timestamp":1793852971760,"version":"4.6.1"},"reference-count":226,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T00:00:00Z","timestamp":1680912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T00:00:00Z","timestamp":1680912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Migraine is an extremely disabling, common neurological disorder characterized by a complex neurobiology, involving a series of central and peripheral nervous system areas and networks. A growing increase in the understanding of migraine pathophysiology in recent years has facilitated translation of that knowledge into novel treatments, which are currently becoming available to patients in many parts of the world and are substantially changing the clinical approach to the disease. In the first part of this review, we will provide an up to date overview of migraine pathophysiology by analyzing the anatomy and function of the main regions involved in the disease, focusing on how these give rise to the plethora of symptoms characterizing the attacks and overall disease. The second part of the paper will discuss the novel therapeutic agents that have emerged for the treatment of migraine, including molecules targeting calcitonin gene-related peptide (gepants and monoclonal antibodies), serotonin 5-HT\n                    <jats:sub>1F<\/jats:sub>\n                    receptor agonists (ditans) and non-invasive neuromodulation, as well as providing a brief overview of new evidence for classic migraine treatments.\n                  <\/jats:p>","DOI":"10.1007\/s00415-023-11706-1","type":"journal-article","created":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T04:02:43Z","timestamp":1680926563000},"page":"3654-3666","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":178,"title":["Migraine: from pathophysiology to treatment"],"prefix":"10.1007","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1933-4049","authenticated-orcid":false,"given":"Francesca","family":"Puledda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa Martins","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanokrat","family":"Suwanlaong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Goadsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,8]]},"reference":[{"issue":"9995","key":"11706_CR1","first-page":"743","volume":"386","author":"Global Burden of Disease Study 2013 Collaborators","year":"2013","unstructured":"Global Burden of Disease Study 2013 Collaborators (2013) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (London, England) 386(9995):743\u2013800","journal-title":"Lancet (London, England)"},{"issue":"2","key":"11706_CR2","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/physrev.00034.2015","volume":"97","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S (2017) Pathophysiology of migraine\u2014a disorder of sensory processing. Physiol Rev 97(2):553\u2013622","journal-title":"Physiol Rev"},{"issue":"5","key":"11706_CR3","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/head.14120","volume":"61","author":"RB Lipton","year":"2021","unstructured":"Lipton RB, Dodick DW, Ailani J, McGill L, Hirman J, Cady R (2021) Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: a novel patient-centered outcome. Headache 61(5):766\u2013776","journal-title":"Headache"},{"key":"11706_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s10194-016-0599-8","volume":"17","author":"C Lampl","year":"2016","unstructured":"Lampl C, Thomas H, Stovner LJ, Tassorelli C, Katsarava Z, La\u00ednez JM et al (2016) Interictal burden attributable to episodic headache: findings from the Eurolight project. J Headache Pain 17:9","journal-title":"J Headache Pain"},{"issue":"Suppl 1","key":"11706_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/head.13300","volume":"58","author":"DW Dodick","year":"2018","unstructured":"Dodick DW (2018) A Phase-by-phase review of migraine pathophysiology. Headache 58(Suppl 1):4\u201316","journal-title":"Headache"},{"issue":"12","key":"11706_CR6","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41582-018-0098-4","volume":"14","author":"N Karsan","year":"2018","unstructured":"Karsan N, Goadsby PJ (2018) Biological insights from the premonitory symptoms of migraine. Nat Rev Neurol 14(12):699\u2013710","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"11706_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/WCO.0b013e32836085f4","volume":"26","author":"A Charles","year":"2013","unstructured":"Charles A (2013) Migraine: a brain state. Curr Opin Neurol 26(3):235\u2013239","journal-title":"Curr Opin Neurol"},{"issue":"9","key":"11706_CR8","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1007\/s00415-017-8434-y","volume":"264","author":"F Puledda","year":"2017","unstructured":"Puledda F, Messina R, Goadsby PJ (2017) An update on migraine: current understanding and future directions. J Neurol 264(9):2031\u20132039","journal-title":"J Neurol"},{"issue":"Pt 3","key":"11706_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1046\/j.1469-7580.1997.19030367.x","volume":"190","author":"PJ Goadsby","year":"1997","unstructured":"Goadsby PJ, Hoskin KL (1997) The distribution of trigeminovascular afferents in the nonhuman primate brain Macaca nemestrina: a c-fos immunocytochemical study. J Anat 190(Pt 3):367\u2013375","journal-title":"J Anat"},{"key":"11706_CR10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1046\/j.1469-7580.1999.19440579.x","volume":"194","author":"KL Hoskin","year":"1999","unstructured":"Hoskin KL, Zagami A, Goadsby PJ (1999) Stimulation of the middle meningeal artery leads to Fos expression in the trigeminocervical nucleus: a comparative study of monkey and cat. J Anat 194:579\u2013588","journal-title":"J Anat"},{"issue":"10","key":"11706_CR11","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nrn3057","volume":"12","author":"S Akerman","year":"2011","unstructured":"Akerman S, Holland PR, Goadsby PJ (2011) Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci 12(10):570\u2013584","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"11706_CR12","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.ncl.2019.07.008","volume":"37","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Holland PR (2019) An update: pathophysiology of migraine. Neurol Clin 37(4):651\u2013671","journal-title":"Neurol Clin"},{"issue":"10","key":"11706_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrneurol.2010.127","volume":"6","author":"TW Ho","year":"2010","unstructured":"Ho TW, Edvinsson L, Goadsby PJ (2010) CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 6(10):573\u2013582","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"11706_CR14","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/head.13529","volume":"59","author":"S Iyengar","year":"2019","unstructured":"Iyengar S, Johnson KW, Ossipov MH, Aurora SK (2019) CGRP and the trigeminal system in migraine. Headache 59(5):659\u2013681","journal-title":"Headache"},{"issue":"12","key":"11706_CR15","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/acn3.113","volume":"1","author":"AS Zagami","year":"2014","unstructured":"Zagami AS, Edvinsson L, Goadsby PJ (2014) Pituitary adenylate cyclase activating polypeptide and migraine. Ann Clin Transl Neurol 1(12):1036\u20131040","journal-title":"Ann Clin Transl Neurol"},{"key":"11706_CR16","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1523\/JNEUROSCI.07-12-04129.1987","volume":"7","author":"S Markowitz","year":"1987","unstructured":"Markowitz S, Saito K, Moskowitz MA (1987) Neurogenically mediated leakage of plasma proteins occurs from blood vessels in dura mater but not brain. J Neurosci 7:4129\u20134136","journal-title":"J Neurosci"},{"key":"11706_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/13543784.10.4.673","volume":"10","author":"A May","year":"2001","unstructured":"May A, Goadsby PJ (2001) Substance P receptor antagonists in the therapy of migraine. Expert Opin Investig Drugs 10:1\u20136","journal-title":"Expert Opin Investig Drugs"},{"key":"11706_CR18","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1124\/mi.5.5.10","volume":"5","author":"SJ Peroutka","year":"2005","unstructured":"Peroutka SJ (2005) Neurogenic inflammation and migraine: implications for therapeutics. Mol Interv 5:306\u2013313","journal-title":"Mol Interv"},{"issue":"3","key":"11706_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00281-018-0676-y","volume":"40","author":"R Ramachandran","year":"2018","unstructured":"Ramachandran R (2018) Neurogenic inflammation and its role in migraine. Semin Immunopathol 40(3):301\u2013314","journal-title":"Semin Immunopathol"},{"issue":"3","key":"11706_CR20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/WCO.0000000000001059","volume":"35","author":"KP Peng","year":"2022","unstructured":"Peng KP, May A, Basedau H (2022) Cycling multisensory changes in migraine: more than a headache. Curr Opin Neurol 35(3):367\u2013372","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"11706_CR21","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1055\/s-0042-1757924","volume":"42","author":"AM Harriott","year":"2022","unstructured":"Harriott AM, Orlova Y (2022) Anatomy and physiology of headache. Semin Neurol 42(4):459\u2013473","journal-title":"Semin Neurol"},{"issue":"3","key":"11706_CR22","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/WCO.0000000000001060","volume":"35","author":"R Messina","year":"2022","unstructured":"Messina R, Gollion C, Christensen RH, Amin FM (2022) Functional MRI in migraine. Curr Opin Neurol 35(3):328\u2013335","journal-title":"Curr Opin Neurol"},{"issue":"8","key":"11706_CR23","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/j.1526-4610.1987.hed2708416.x","volume":"27","author":"NH Raskin","year":"1987","unstructured":"Raskin NH, Hosobuchi Y, Lamb S (1987) Headache may arise from perturbation of brain. Headache 27(8):416\u2013420","journal-title":"Headache"},{"issue":"7","key":"11706_CR24","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nm0795-658","volume":"1","author":"C Weiller","year":"1995","unstructured":"Weiller C, May A, Limmroth V, Juptner M, Kaube H, Schayck RV et al (1995) Brain stem activation in spontaneous human migraine attacks. Nat Med 1(7):658\u2013660","journal-title":"Nat Med"},{"issue":"9261","key":"11706_CR25","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/S0140-6736(00)04250-1","volume":"357","author":"A Bahra","year":"2001","unstructured":"Bahra A, Matharu MS, Buchel C, Frackowiak RS, Goadsby PJ (2001) Brainstem activation specific to migraine headache. Lancet 357(9261):1016\u20131017","journal-title":"Lancet"},{"issue":"6","key":"11706_CR26","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1523\/JNEUROSCI.4496-10.2011","volume":"31","author":"A Stankewitz","year":"2011","unstructured":"Stankewitz A, Aderjan D, Eippert F, May A (2011) Trigeminal nociceptive transmission in migraineurs predicts migraine attacks. J Neurosci 31(6):1937\u20131943","journal-title":"J Neurosci"},{"issue":"1","key":"11706_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0006-8993(89)91537-0","volume":"476","author":"PJ Goadsby","year":"1989","unstructured":"Goadsby PJ, Duckworth JW (1989) Low frequency stimulation of the locus coeruleus reduces regional cerebral blood flow in the spinalized cat. Brain Res 476(1):71\u201377","journal-title":"Brain Res"},{"issue":"11","key":"11706_CR28","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/0333102414565672","volume":"35","author":"LV Vinogradova","year":"2015","unstructured":"Vinogradova LV (2015) Comparative potency of sensory-induced brainstem activation to trigger spreading depression and seizures in the cortex of awake rats: implications for the pathophysiology of migraine aura. Cephalalgia 35(11):979\u2013986","journal-title":"Cephalalgia"},{"issue":"5","key":"11706_CR29","doi-asserted-by":"publisher","first-page":"Rc213","DOI":"10.1523\/JNEUROSCI.22-05-j0002.2002","volume":"22","author":"YE Knight","year":"2002","unstructured":"Knight YE, Bartsch T, Kaube H, Goadsby PJ (2002) P\/Q-type calcium-channel blockade in the periaqueductal gray facilitates trigeminal nociception: a functional genetic link for migraine? J Neurosci 22(5):Rc213","journal-title":"J Neurosci"},{"issue":"4","key":"11706_CR30","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0306-4522(01)00303-7","volume":"106","author":"YE Knight","year":"2001","unstructured":"Knight YE, Goadsby PJ (2001) The periaqueductal grey matter modulates trigeminovascular input: a role in migraine? Neuroscience 106(4):793\u2013800","journal-title":"Neuroscience"},{"issue":"21","key":"11706_CR31","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1212\/WNL.0000000000001610","volume":"84","author":"IL Kroger","year":"2015","unstructured":"Kroger IL, May A (2015) Triptan-induced disruption of trigemino-cortical connectivity. Neurology 84(21):2124\u20132131","journal-title":"Neurology"},{"issue":"2\u20133","key":"11706_CR32","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/0304-3959(96)03118-1","volume":"67","author":"PJ Goadsby","year":"1996","unstructured":"Goadsby PJ, Hoskin KL (1996) Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B\/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine? Pain 67(2\u20133):355\u2013359","journal-title":"Pain"},{"issue":"1","key":"11706_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/ana.410290116","volume":"29","author":"PJ Goadsby","year":"1991","unstructured":"Goadsby PJ, Gundlach AL (1991) Localization of 3H-dihydroergotamine-binding sites in the cat central nervous system: relevance to migraine. Ann Neurol 29(1):91\u201394","journal-title":"Ann Neurol"},{"issue":"Pt 1","key":"11706_CR34","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/brain\/119.1.249","volume":"119","author":"KL Hoskin","year":"1996","unstructured":"Hoskin KL, Kaube H, Goadsby PJ (1996) Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study. Brain J Neurol 119(Pt 1):249\u2013256","journal-title":"Brain J Neurol"},{"issue":"14","key":"11706_CR35","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1177\/0333102415576723","volume":"35","author":"P Pozo-Rosich","year":"2015","unstructured":"Pozo-Rosich P, Storer RJ, Charbit AR, Goadsby PJ (2015) Periaqueductal gray calcitonin gene-related peptide modulates trigeminovascular neurons. Cephalalgia 35(14):1298\u20131307","journal-title":"Cephalalgia"},{"issue":"7","key":"11706_CR36","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/sj.bjp.0705807","volume":"142","author":"RJ Storer","year":"2004","unstructured":"Storer RJ, Akerman S, Goadsby PJ (2004) Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 142(7):1171\u20131181","journal-title":"Br J Pharmacol"},{"issue":"13","key":"11706_CR37","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1177\/03331024221110111","volume":"42","author":"M Martins-Oliveira","year":"2022","unstructured":"Martins-Oliveira M, Akerman S, Holland PR, Tavares I, Goadsby PJ (2022) Pharmacological modulation of ventral tegmental area neurons elicits changes in trigeminovascular sensory processing and is accompanied by glycemic changes: Implications for migraine. Cephalalgia Int J Headache 42(13):1359\u20131374","journal-title":"Cephalalgia Int J Headache"},{"key":"11706_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.nbd.2017.01.005","volume":"101","author":"M Martins-Oliveira","year":"2017","unstructured":"Martins-Oliveira M, Akerman S, Holland PR, Hoffmann JR, Tavares I, Goadsby PJ (2017) Neuroendocrine signaling modulates specific neural networks relevant to migraine. Neurobiol Dis 101:16\u201326","journal-title":"Neurobiol Dis"},{"key":"11706_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2021.147629","volume":"1770","author":"M Martins-Oliveira","year":"2021","unstructured":"Martins-Oliveira M, Tavares I, Goadsby PJ (2021) Was it something I ate? Understanding the bidirectional interaction of migraine and appetite neural circuits. Brain Res 1770:147629","journal-title":"Brain Res"},{"issue":"5","key":"11706_CR40","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s00415-020-10344-1","volume":"268","author":"N Karsan","year":"2021","unstructured":"Karsan N, Bose P, Newman J, Goadsby PJ (2021) Are some patient-perceived migraine triggers simply early manifestations of the attack? J Neurol 268(5):1885\u20131893","journal-title":"J Neurol"},{"issue":"8","key":"11706_CR41","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/s41582-019-0216-y","volume":"15","author":"L Edvinsson","year":"2019","unstructured":"Edvinsson L, Haanes KA, Warfvinge K (2019) Does inflammation have a role in migraine? Nat Rev Neurol 15(8):483\u2013490","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"11706_CR42","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s10194-021-01382-9","volume":"23","author":"L Zhang","year":"2022","unstructured":"Zhang L, Lu C, Kang L, Li Y, Tang W, Zhao D et al (2022) Temporal characteristics of astrocytic activation in the TNC in a mice model of pain induced by recurrent dural infusion of inflammatory soup. J Headache Pain 23(1):8","journal-title":"J Headache Pain"},{"issue":"1","key":"11706_CR43","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s10194-022-01392-1","volume":"23","author":"F-J Hsiao","year":"2022","unstructured":"Hsiao F-J, Chen W-T, Pan L-LH, Liu H-Y, Wang Y-F, Chen S-P et al (2022) Dynamic brainstem and somatosensory cortical excitability during migraine cycles. J Headache Pain 23(1):21","journal-title":"J Headache Pain"},{"issue":"Pt 7","key":"11706_CR44","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1093\/brain\/aww097","volume":"139","author":"LH Schulte","year":"2016","unstructured":"Schulte LH, May A (2016) The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. Brain J Neurol 139(Pt 7):1987\u20131993","journal-title":"Brain J Neurol"},{"issue":"7","key":"11706_CR45","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1097\/j.pain.0000000000001531","volume":"160","author":"KP Peng","year":"2019","unstructured":"Peng KP, May A (2019) Migraine understood as a sensory threshold disease. Pain 160(7):1494\u20131501","journal-title":"Pain"},{"issue":"13","key":"11706_CR46","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1177\/0333102419867280","volume":"39","author":"A May","year":"2019","unstructured":"May A, Burstein R (2019) Hypothalamic regulation of headache and migraine. Cephalalgia Int J Headache 39(13):1710\u20131719","journal-title":"Cephalalgia Int J Headache"},{"issue":"4","key":"11706_CR47","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/ana.25697","volume":"87","author":"LH Schulte","year":"2020","unstructured":"Schulte LH, Mehnert J, May A (2020) Longitudinal neuroimaging over 30 days: temporal characteristics of migraine. Ann Neurol 87(4):646\u2013651","journal-title":"Ann Neurol"},{"issue":"10","key":"11706_CR48","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1111\/j.1526-4610.2007.00776.x","volume":"47","author":"M Denuelle","year":"2007","unstructured":"Denuelle M, Fabre N, Payoux P, Chollet F, Geraud G (2007) Hypothalamic activation in spontaneous migraine attacks. Headache 47(10):1418\u20131426","journal-title":"Headache"},{"issue":"Pt 1","key":"11706_CR49","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/brain\/awt320","volume":"137","author":"FH Maniyar","year":"2014","unstructured":"Maniyar FH, Sprenger T, Monteith T, Schankin C, Goadsby PJ (2014) Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain J Neurol 137(Pt 1):232\u2013241","journal-title":"Brain J Neurol"},{"issue":"1","key":"11706_CR50","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s10194-019-0986-z","volume":"20","author":"MJ Lee","year":"2019","unstructured":"Lee MJ, Park BY, Cho S, Kim ST, Park H, Chung CS (2019) Increased connectivity of pain matrix in chronic migraine: a resting-state functional MRI study. J Headache Pain 20(1):29","journal-title":"J Headache Pain"},{"issue":"21","key":"11706_CR51","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1212\/WNL.0000000000003963","volume":"88","author":"LH Schulte","year":"2017","unstructured":"Schulte LH, Allers A, May A (2017) Hypothalamus as a mediator of chronic migraine: evidence from high-resolution fMRI. Neurology 88(21):2011\u20132016","journal-title":"Neurology"},{"key":"11706_CR52","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.neuroscience.2013.06.014","volume":"248","author":"R Kagan","year":"2013","unstructured":"Kagan R, Kainz V, Burstein R, Noseda R (2013) Hypothalamic and basal ganglia projections to the posterior thalamus: possible role in modulation of migraine headache and photophobia. Neuroscience 248:359\u2013368","journal-title":"Neuroscience"},{"issue":"1","key":"11706_CR53","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/(SICI)1096-9861(19981012)400:1<125::AID-CNE9>3.0.CO;2-B","volume":"400","author":"A Malick","year":"1998","unstructured":"Malick A, Burstein R (1998) Cells of origin of the trigeminohypothalamic tract in the rat. J Comp Neurol 400(1):125\u2013144","journal-title":"J Comp Neurol"},{"issue":"8","key":"11706_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073022","volume":"8","author":"K Abdallah","year":"2013","unstructured":"Abdallah K, Artola A, Monconduit L, Dallel R, Luccarini P (2013) Bilateral descending hypothalamic projections to the spinal trigeminal nucleus caudalis in rats. PLoS\u00a0One 8(8):e73022","journal-title":"PLoS\u00a0One"},{"issue":"8","key":"11706_CR55","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1093\/brain\/awac104","volume":"145","author":"M Watanabe","year":"2022","unstructured":"Watanabe M, Kopruszinski CM, Moutal A, Ikegami D, Khanna R, Chen Y et al (2022) Dysregulation of serum prolactin links the hypothalamus with female nociceptors to promote migraine. Brain 145(8):2894\u20132909","journal-title":"Brain"},{"issue":"11","key":"11706_CR56","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41582-019-0255-4","volume":"15","author":"EC Gross","year":"2019","unstructured":"Gross EC, Lisicki M, Fischer D, Sandor PS, Schoenen J (2019) The metabolic face of migraine\u2014from pathophysiology to treatment. Nat Rev Neurol 15(11):627\u2013643","journal-title":"Nat Rev Neurol"},{"issue":"40","key":"11706_CR57","doi-asserted-by":"publisher","first-page":"14204","DOI":"10.1523\/JNEUROSCI.3285-11.2011","volume":"31","author":"R Noseda","year":"2011","unstructured":"Noseda R, Jakubowski M, Kainz V, Borsook D, Burstein R (2011) Cortical projections of functionally identified thalamic trigeminovascular neurons: implications for migraine headache and its associated symptoms. J Neurosci 31(40):14204\u201314217","journal-title":"J Neurosci"},{"issue":"Suppl 2","key":"11706_CR58","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/head.13083","volume":"57","author":"R Noseda","year":"2017","unstructured":"Noseda R, Borsook D, Burstein R (2017) Neuropeptides and neurotransmitters that modulate thalamo-cortical pathways relevant to migraine headache. Headache 57(Suppl 2):97\u2013111","journal-title":"Headache"},{"issue":"1","key":"11706_CR59","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ana.21994","volume":"68","author":"R Burstein","year":"2010","unstructured":"Burstein R, Jakubowski M, Garcia-Nicas E, Kainz V, Bajwa Z, Hargreaves R et al (2010) Thalamic sensitization transforms localized pain into widespread allodynia. Ann Neurol 68(1):81\u201391","journal-title":"Ann Neurol"},{"issue":"2","key":"11706_CR60","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1152\/jn.1998.79.2.964","volume":"79","author":"R Burstein","year":"1998","unstructured":"Burstein R, Yamamura H, Malick A, Strassman AM (1998) Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 79(2):964\u2013982","journal-title":"J Neurophysiol"},{"issue":"6609","key":"11706_CR61","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/384560a0","volume":"384","author":"AM Strassman","year":"1996","unstructured":"Strassman AM, Raymond SA, Burstein R (1996) Sensitization of meningeal sensory neurons and the origin of headaches. Nature 384(6609):560\u2013564","journal-title":"Nature"},{"key":"11706_CR62","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.2147\/JPR.S329280","volume":"15","author":"K Suzuki","year":"2022","unstructured":"Suzuki K, Suzuki S, Shiina T, Kobayashi S, Hirata K (2022) Central sensitization in migraine: a narrative review. J Pain Res 15:2673\u20132682","journal-title":"J Pain Res"},{"issue":"Pt 7","key":"11706_CR63","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1093\/brain\/aww119","volume":"139","author":"R Noseda","year":"2016","unstructured":"Noseda R, Bernstein CA, Nir RR, Lee AJ, Fulton AB, Bertisch SM et al (2016) Migraine photophobia originating in cone-driven retinal pathways. Brain 139(Pt 7):1971\u20131986","journal-title":"Brain"},{"issue":"2","key":"11706_CR64","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nn.2475","volume":"13","author":"R Noseda","year":"2010","unstructured":"Noseda R, Kainz V, Jakubowski M, Gooley JJ, Saper CB, Digre K et al (2010) A neural mechanism for exacerbation of headache by light. Nat Neurosci 13(2):239\u2013245","journal-title":"Nat Neurosci"},{"issue":"40","key":"11706_CR65","doi-asserted-by":"publisher","first-page":"13800","DOI":"10.1523\/JNEUROSCI.2154-15.2015","volume":"35","author":"S Magon","year":"2015","unstructured":"Magon S, May A, Stankewitz A, Goadsby PJ, Tso AR, Ashina M et al (2015) Morphological abnormalities of thalamic subnuclei in migraine: a multicenter MRI study at 3 Tesla. J Neurosci 35(40):13800\u201313806","journal-title":"J Neurosci"},{"issue":"4","key":"11706_CR66","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/hbm.22266","volume":"35","author":"C Granziera","year":"2014","unstructured":"Granziera C, Daducci A, Romascano D, Roche A, Helms G, Krueger G et al (2014) Structural abnormalities in the thalamus of migraineurs with aura: a multiparametric study at 3 T. Hum Brain Mapp 35(4):1461\u20131468","journal-title":"Hum Brain Mapp"},{"issue":"14","key":"11706_CR67","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1177\/0333102415578428","volume":"35","author":"R Messina","year":"2015","unstructured":"Messina R, Rocca MA, Colombo B, Pagani E, Falini A, Comi G et al (2015) White matter microstructure abnormalities in pediatric migraine patients. Cephalalgia 35(14):1278\u20131286","journal-title":"Cephalalgia"},{"key":"11706_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2020.102361","volume":"28","author":"A Hougaard","year":"2020","unstructured":"Hougaard A, Nielsen SH, Gaist D, Puonti O, Garde E, Reislev NL et al (2020) Migraine with aura in women is not associated with structural thalamic abnormalities. Neuroimage Clin 28:102361","journal-title":"Neuroimage Clin"},{"issue":"7","key":"11706_CR69","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1177\/0333102417729113","volume":"38","author":"FM Amin","year":"2018","unstructured":"Amin FM, Hougaard A, Magon S, Sprenger T, Wolfram F, Rostrup E et al (2018) Altered thalamic connectivity during spontaneous attacks of migraine without aura: a resting-state fMRI study. Cephalalgia 38(7):1237\u20131244","journal-title":"Cephalalgia"},{"issue":"30","key":"11706_CR70","doi-asserted-by":"publisher","first-page":"8026","DOI":"10.1523\/JNEUROSCI.1038-16.2016","volume":"36","author":"DJ Hodkinson","year":"2016","unstructured":"Hodkinson DJ, Wilcox SL, Veggeberg R, Noseda R, Burstein R, Borsook D et al (2016) Increased amplitude of thalamocortical low-frequency oscillations in patients with migraine. J Neurosci 36(30):8026\u20138036","journal-title":"J Neurosci"},{"issue":"23","key":"11706_CR71","doi-asserted-by":"publisher","first-page":"e2706","DOI":"10.1212\/WNL.0000000000007607","volume":"92","author":"Y Tu","year":"2019","unstructured":"Tu Y, Fu Z, Zeng F, Maleki N, Lan L, Li Z et al (2019) Abnormal thalamocortical network dynamics in migraine. Neurology 92(23):e2706\u2013e2716","journal-title":"Neurology"},{"issue":"1","key":"11706_CR72","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s10194-020-01210-6","volume":"22","author":"M Lim","year":"2021","unstructured":"Lim M, Jassar H, Kim DJ, Nascimento TD, DaSilva AF (2021) Differential alteration of fMRI signal variability in the ascending trigeminal somatosensory and pain modulatory pathways in migraine. J Headache Pain 22(1):4","journal-title":"J Headache Pain"},{"issue":"3","key":"11706_CR73","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.nbd.2006.04.003","volume":"23","author":"KG Shields","year":"2006","unstructured":"Shields KG, Goadsby PJ (2006) Serotonin receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: a migraine target? Neurobiol Dis 23(3):491\u2013501","journal-title":"Neurobiol Dis"},{"issue":"Pt 1","key":"11706_CR74","first-page":"86","volume":"128","author":"KG Shields","year":"2005","unstructured":"Shields KG, Goadsby PJ (2005) Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? Brain 128(Pt 1):86\u201397","journal-title":"Brain"},{"issue":"1","key":"11706_CR75","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/ejn.12753","volume":"41","author":"N Tepe","year":"2015","unstructured":"Tepe N, Filiz A, Dilekoz E, Akcali D, Sara Y, Charles A et al (2015) The thalamic reticular nucleus is activated by cortical spreading depression in freely moving rats: prevention by acute valproate administration. Eur J Neurosci 41(1):120\u2013128","journal-title":"Eur J Neurosci"},{"issue":"2","key":"11706_CR76","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.nbd.2009.10.007","volume":"37","author":"AP Andreou","year":"2010","unstructured":"Andreou AP, Shields KG, Goadsby PJ (2010) GABA and valproate modulate trigeminovascular nociceptive transmission in the thalamus. Neurobiol Dis 37(2):314\u2013323","journal-title":"Neurobiol Dis"},{"issue":"9","key":"11706_CR77","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1093\/brain\/awq224","volume":"133","author":"O Summ","year":"2010","unstructured":"Summ O, Charbit AR, Andreou AP, Goadsby PJ (2010) Modulation of nocioceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus. Brain J Neurol 133(9):2540\u20132548","journal-title":"Brain J Neurol"},{"issue":"2","key":"11706_CR78","first-page":"336","volume":"15","author":"F Puledda","year":"2018","unstructured":"Puledda F, Shields K (2018) Non-pharmacological approaches for migraine. Neurother J Am Soc Exp Neurother 15(2):336\u2013345","journal-title":"Neurother J Am Soc Exp Neurother"},{"issue":"Pt 7","key":"11706_CR79","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1093\/brain\/aww118","volume":"139","author":"AP Andreou","year":"2016","unstructured":"Andreou AP, Holland PR, Akerman S, Summ O, Fredrick J, Goadsby PJ (2016) Transcranial magnetic stimulation and potential cortical and trigeminothalamic mechanisms in migraine. Brain J Neurol 139(Pt 7):2002\u20132014","journal-title":"Brain J Neurol"},{"issue":"4","key":"11706_CR80","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/ana.410090406","volume":"9","author":"J Olesen","year":"1981","unstructured":"Olesen J, Larsen B, Lauritzen M (1981) Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol 9(4):344\u2013352","journal-title":"Ann Neurol"},{"issue":"2","key":"11706_CR81","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3390\/diagnostics13020252","volume":"13","author":"E Barral","year":"2023","unstructured":"Barral E, Martins Silva E, Garc\u00eda-Azor\u00edn D, Viana M, Puledda F (2023) Differential diagnosis of visual phenomena associated with migraine: spotlight on aura and visual snow syndrome. Diagnostics 13(2):252","journal-title":"Diagnostics"},{"key":"11706_CR82","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1152\/jn.1944.7.6.359","volume":"7","author":"AAP Le\u00e3o","year":"1944","unstructured":"Le\u00e3o AAP (1944) Spreading depression of activity in the cerebral cortex. J Neurophysiol 7:359\u2013390","journal-title":"J Neurophysiol"},{"issue":"8","key":"11706_CR83","doi-asserted-by":"publisher","first-page":"4687","DOI":"10.1073\/pnas.071582498","volume":"98","author":"N Hadjikhani","year":"2001","unstructured":"Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischl B et al (2001) Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA 98(8):4687\u20134692","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"11706_CR84","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/nm0202-136","volume":"8","author":"H Bolay","year":"2002","unstructured":"Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA (2002) Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 8(2):136\u2013142","journal-title":"Nat Med"},{"issue":"5","key":"11706_CR85","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/ana.22329","volume":"69","author":"X Zhang","year":"2011","unstructured":"Zhang X, Levy D, Kainz V, Noseda R, Jakubowski M, Burstein R (2011) Activation of central trigeminovascular neurons by cortical spreading depression. Ann Neurol 69(5):855\u2013865","journal-title":"Ann Neurol"},{"issue":"30","key":"11706_CR86","doi-asserted-by":"publisher","first-page":"7149","DOI":"10.1523\/JNEUROSCI.0576-17.2017","volume":"37","author":"A Melo-Carrillo","year":"2017","unstructured":"Melo-Carrillo A, Noseda R, Nir RR, Schain AJ, Stratton J, Strassman AM et al (2017) Selective inhibition of trigeminovascular neurons by fremanezumab: a humanized monoclonal anti-CGRP antibody. J Neurosci 37(30):7149\u20137163","journal-title":"J Neurosci"},{"issue":"4, Headache","key":"11706_CR87","first-page":"1009","volume":"24","author":"A Charles","year":"2018","unstructured":"Charles A (2018) The migraine aura. Continuum (Minneapolis, Minn). 24(4, Headache):1009\u20131022","journal-title":"Continuum (Minneapolis, Minn)."},{"key":"11706_CR88","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/ana.10025","volume":"51","author":"PJ Goadsby","year":"2002","unstructured":"Goadsby PJ (2002) Parallel concept of migraine pathogenesis. Ann Neurol 51:140","journal-title":"Ann Neurol"},{"issue":"4","key":"11706_CR89","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/WCO.0000000000000573","volume":"31","author":"R Messina","year":"2018","unstructured":"Messina R, Filippi M, Goadsby PJ (2018) Recent advances in headache neuroimaging. Curr Opin Neurol 31(4):379\u2013385","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"11706_CR90","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00702-019-02089-7","volume":"127","author":"G Coppola","year":"2020","unstructured":"Coppola G, Parisi V, Di Renzo A, Pierelli F (2020) Cortical pain processing in migraine. J Neural Transm (Vienna) 127(4):551\u2013566","journal-title":"J Neural Transm (Vienna)"},{"issue":"5","key":"11706_CR91","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1177\/0333102418795163","volume":"39","author":"S Magon","year":"2019","unstructured":"Magon S, May A, Stankewitz A, Goadsby PJ, Schankin C, Ashina M et al (2019) Cortical abnormalities in episodic migraine: a multi-center 3T MRI study. Cephalalgia 39(5):665\u2013673","journal-title":"Cephalalgia"},{"issue":"2","key":"11706_CR92","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/ane.13536","volume":"145","author":"S Park","year":"2022","unstructured":"Park S, Lee DA, Lee HJ, Shin KJ, Park KM (2022) Brain networks in migraine with and without aura: an exploratory arterial spin labeling MRI study. Acta Neurol Scand 145(2):208\u2013214","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"11706_CR93","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1177\/0271678X17719430","volume":"39","author":"N Arngrim","year":"2019","unstructured":"Arngrim N, Hougaard A, Schytz HW, Vestergaard MB, Britze J, Amin FM et al (2019) Effect of hypoxia on BOLD fMRI response and total cerebral blood flow in migraine with aura patients. J Cereb Blood Flow Metab 39(4):680\u2013689","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"11706_CR94","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s10194-016-0716-8","volume":"18","author":"P Farago","year":"2017","unstructured":"Farago P, Tuka B, Toth E, Szabo N, Kiraly A, Csete G et al (2017) Interictal brain activity differs in migraine with and without aura: resting state fMRI study. J Headache Pain 18(1):8","journal-title":"J Headache Pain"},{"issue":"4","key":"11706_CR95","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1097\/j.pain.0000000000001770","volume":"161","author":"D Vereb","year":"2020","unstructured":"Vereb D, Szabo N, Tuka B, Tajti J, Kiraly A, Farago P et al (2020) Temporal instability of salience network activity in migraine with aura. Pain 161(4):856\u2013864","journal-title":"Pain"},{"issue":"1","key":"11706_CR96","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s10194-019-1002-3","volume":"20","author":"A Russo","year":"2019","unstructured":"Russo A, Tessitore A, Silvestro M, Di Nardo F, Trojsi F, Del Santo T et al (2019) Advanced visual network and cerebellar hyperresponsiveness to trigeminal nociception in migraine with aura. J Headache Pain 20(1):46","journal-title":"J Headache Pain"},{"key":"11706_CR97","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3389\/fneur.2019.01325","volume":"10","author":"F Puledda","year":"2019","unstructured":"Puledda F, Ffytche DH, O\u2019Daly O, Goadsby PJ (2019) Imaging the visual network in the migraine spectrum. Front Neurol 10:1325","journal-title":"Front Neurol"},{"key":"11706_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2022.967103","volume":"15","author":"ZW Wang","year":"2022","unstructured":"Wang ZW, Yin ZH, Wang X, Zhang YT, Xu T, Du JR et al (2022) Brain structural and functional changes during menstrual migraine: relationships with pain. Front Mol Neurosci 15:967103","journal-title":"Front Mol Neurosci"},{"issue":"8","key":"11706_CR99","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0333102412445622","volume":"32","author":"N Maleki","year":"2012","unstructured":"Maleki N, Becerra L, Brawn J, Bigal M, Burstein R, Borsook D (2012) Concurrent functional and structural cortical alterations in migraine. Cephalalgia Int J Headache 32(8):607\u2013620","journal-title":"Cephalalgia Int J Headache"},{"issue":"6","key":"11706_CR100","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa123","volume":"143","author":"L Sheng","year":"2020","unstructured":"Sheng L, Zhao P, Ma H, Yuan C, Zhong J, Dai Z et al (2020) A lack of consistent brain grey matter alterations in migraine. Brain 143(6):e45","journal-title":"Brain"},{"key":"11706_CR101","doi-asserted-by":"publisher","first-page":"1022793","DOI":"10.3389\/fneur.2022.1022793","volume":"13","author":"ZH Chen","year":"2022","unstructured":"Chen ZH, Cui YL, Sun JT, Li YT, Zhang C, Zhang YM et al (2022) The brain structure and function abnormalities of migraineurs: a systematic review and neuroimaging meta-analysis. Front Neurol 13:1022793","journal-title":"Front Neurol"},{"issue":"15","key":"11706_CR102","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1212\/WNL.0b013e3182a8235b","volume":"81","author":"AG Hamedani","year":"2013","unstructured":"Hamedani AG, Rose KM, Peterlin BL, Mosley TH, Coker LH, Jack CR et al (2013) Migraine and white matter hyperintensities: the ARIC MRI study. Neurology 81(15):1308\u20131313","journal-title":"Neurology"},{"issue":"2","key":"11706_CR103","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1468-2982.2009.01904.x","volume":"30","author":"MC Kruit","year":"2010","unstructured":"Kruit MC, van Buchem MA, Launer LJ, Terwindt GM, Ferrari MD (2010) Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: the population-based MRI CAMERA study. Cephalalgia 30(2):129\u2013136","journal-title":"Cephalalgia"},{"issue":"6","key":"11706_CR104","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1161\/STROKEAHA.114.005447","volume":"45","author":"T Monteith","year":"2014","unstructured":"Monteith T, Gardener H, Rundek T, Dong C, Yoshita M, Elkind MS et al (2014) Migraine, white matter hyperintensities, and subclinical brain infarction in a diverse community: the northern Manhattan study. Stroke 45(6):1830\u20131832","journal-title":"Stroke"},{"issue":"1","key":"11706_CR105","doi-asserted-by":"publisher","first-page":"10881","DOI":"10.1038\/s41598-021-90341-0","volume":"11","author":"LA Dobrynina","year":"2021","unstructured":"Dobrynina LA, Suslina AD, Gubanova MV, Belopasova AV, Sergeeva AN, Evers S et al (2021) White matter hyperintensity in different migraine subtypes. Sci Rep 11(1):10881","journal-title":"Sci Rep"},{"key":"11706_CR106","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-022-02015-x","author":"SR Ahmed","year":"2022","unstructured":"Ahmed SR, Mohamed AAM, Salem HH, Helmy S, Moustafa RR, Borham SMF (2022) Association of white matter hyperintensities with migraine phenotypes and response to treatment. Acta Neurol Belg. https:\/\/doi.org\/10.1007\/s13760-022-02015-x","journal-title":"Acta Neurol Belg"},{"issue":"12","key":"11706_CR107","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1111\/j.1468-2982.2007.01466.x","volume":"27","author":"G Coppola","year":"2007","unstructured":"Coppola G, Ambrosini A, Di Clemente L, Magis D, Fumal A, Gerard P et al (2007) Interictal abnormalities of gamma band activity in visual evoked responses in migraine: an indication of thalamocortical dysrhythmia? Cephalalgia Int J Headache 27(12):1360\u20131367","journal-title":"Cephalalgia Int J Headache"},{"issue":"Pt 9","key":"11706_CR108","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1093\/brain\/awg206","volume":"126","author":"A Ambrosini","year":"2003","unstructured":"Ambrosini A, Rossi P, De Pasqua V, Pierelli F, Schoenen J (2003) Lack of habituation causes high intensity dependence of auditory evoked cortical potentials in migraine. Brain J Neurol 126(Pt 9):2009\u20132015","journal-title":"Brain J Neurol"},{"issue":"Pt 2","key":"11706_CR109","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/brain\/121.2.233","volume":"121","author":"J Afra","year":"1998","unstructured":"Afra J, Cecchini AP, De Pasqua V, Albert A, Schoenen J (1998) Visual evoked potentials during long periods of pattern-reversal stimulation in migraine. Brain J Neurol 121(Pt 2):233\u2013241","journal-title":"Brain J Neurol"},{"key":"11706_CR110","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1129-2377-14-65","volume":"14","author":"G Coppola","year":"2013","unstructured":"Coppola G, Di Lorenzo C, Schoenen J, Pierelli F (2013) Habituation and sensitization in primary headaches. J Headache Pain 14:65","journal-title":"J Headache Pain"},{"issue":"7","key":"11706_CR111","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/ng.2307","volume":"44","author":"T Freilinger","year":"2012","unstructured":"Freilinger T, Anttila V, de Vries B, Malik R, Kallela M, Terwindt GM et al (2012) Genome-wide association analysis identifies susceptibility loci for migraine without aura. Nat Genet 44(7):777\u2013782","journal-title":"Nat Genet"},{"issue":"3","key":"11706_CR112","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/WCO.0000000000000436","volume":"30","author":"S Younis","year":"2017","unstructured":"Younis S, Hougaard A, Vestergaard MB, Larsson HBW, Ashina M (2017) Migraine and magnetic resonance spectroscopy: a systematic review. Curr Opin Neurol 30(3):246\u2013262","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"11706_CR113","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41572-021-00328-4","volume":"8","author":"MD Ferrari","year":"2022","unstructured":"Ferrari MD, Goadsby PJ, Burstein R, Kurth T, Ayata C, Charles A et al (2022) Migraine. Nat Rev Dis Primers 8(1):2","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"11706_CR114","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/WCO.0000000000000935","volume":"34","author":"D Moreno-Ajona","year":"2021","unstructured":"Moreno-Ajona D, Villar-Mart\u00ednez MD, Goadsby PJ (2021) Targets for migraine treatment: beyond calcitonin gene-related peptide. Curr Opin Neurol 34(3):363\u2013372","journal-title":"Curr Opin Neurol"},{"issue":"9","key":"11706_CR115","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1111\/head.14388","volume":"62","author":"ML Garelja","year":"2022","unstructured":"Garelja ML, Hay DL (2022) A narrative review of the calcitonin peptide family and associated receptors as migraine targets: calcitonin gene-related peptide and beyond. Headache 62(9):1093\u20131104","journal-title":"Headache"},{"issue":"2","key":"11706_CR116","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/head.14067","volume":"61","author":"CR Houts","year":"2021","unstructured":"Houts CR, McGinley JS, Nishida TK, Buse DC, Wirth RJ, Dodick DW et al (2021) Systematic review of outcomes and endpoints in acute migraine clinical trials. Headache 61(2):263\u2013275","journal-title":"Headache"},{"issue":"2","key":"11706_CR117","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/head.14069","volume":"61","author":"JS McGinley","year":"2021","unstructured":"McGinley JS, Houts CR, Nishida TK, Buse DC, Lipton RB, Goadsby PJ et al (2021) Systematic review of outcomes and endpoints in preventive migraine clinical trials. Headache 61(2):253\u2013262","journal-title":"Headache"},{"issue":"1","key":"11706_CR118","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s10194-022-01429-5","volume":"23","author":"SH Lo","year":"2022","unstructured":"Lo SH, Gallop K, Smith T, Powell L, Johnston K, Hubig LT et al (2022) Real-world experience of interictal burden and treatment in migraine: a qualitative interview study. J Headache Pain 23(1):65","journal-title":"J Headache Pain"},{"issue":"5","key":"11706_CR119","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S0301-0082(00)00010-1","volume":"62","author":"PJ Goadsby","year":"2000","unstructured":"Goadsby PJ (2000) The pharmacology of headache. Prog Neurobiol 62(5):509\u2013525","journal-title":"Prog Neurobiol"},{"issue":"7","key":"11706_CR120","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/j.1526-4610.1994.hed3407394.x","volume":"34","author":"PJ Goadsby","year":"1994","unstructured":"Goadsby PJ, Edvinsson L (1994) Joint 1994 Wolff Award Presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache 34(7):394\u2013399","journal-title":"Headache"},{"issue":"8","key":"11706_CR121","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1046\/j.1468-2982.2002.00404.x","volume":"22","author":"MD Ferrari","year":"2002","unstructured":"Ferrari MD, Goadsby PJ, Roon KI, Lipton RB (2002) Triptans (serotonin, 5-HT1B\/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia Int J Headache 22(8):633\u2013658","journal-title":"Cephalalgia Int J Headache"},{"issue":"13","key":"11706_CR122","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1001\/jama.297.13.1443","volume":"297","author":"JL Brandes","year":"2007","unstructured":"Brandes JL, Kudrow D, Stark SR, O\u2019Carroll CP, Adelman JU, O\u2019Donnell FJ et al (2007) Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA 297(13):1443\u20131454","journal-title":"JAMA"},{"issue":"2","key":"11706_CR123","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/01.wnl.0000316800.22949.20","volume":"71","author":"SD Silberstein","year":"2008","unstructured":"Silberstein SD, Mannix LK, Goldstein J, Couch JR, Byrd SC, Ames MH et al (2008) Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology 71(2):114\u2013121","journal-title":"Neurology"},{"issue":"4","key":"11706_CR124","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1212\/WNL.0000000000011216","volume":"96","author":"DS van Casteren","year":"2021","unstructured":"van Casteren DS, Kurth T, Danser AHJ, Terwindt GM, MaassenVanDenBrink A (2021) Sex differences in response to triptans: a systematic review and meta-analysis. Neurology 96(4):162\u2013170","journal-title":"Neurology"},{"issue":"1","key":"11706_CR125","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s10194-022-01502-z","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Lampl C, Amin FM, Braschinsky M, Deligianni C, Ulud\u00fcz D et al (2022) European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain 23(1):133","journal-title":"J Headache Pain"},{"issue":"1","key":"11706_CR126","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s10194-020-01110-9","volume":"21","author":"L Lombard","year":"2020","unstructured":"Lombard L, Farrar M, Ye W, Kim Y, Cotton S, Buchanan AS et al (2020) A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication. J Headache Pain 21(1):41","journal-title":"J Headache Pain"},{"key":"11706_CR127","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.798695","volume":"13","author":"JW Wu","year":"2022","unstructured":"Wu JW, Lai PY, Chen YL, Wang YF, Lirng JF, Chen ST et al (2022) The use of neuroimaging for predicting sumatriptan treatment response in patients with migraine. Front Neurol 13:798695","journal-title":"Front Neurol"},{"issue":"2","key":"11706_CR128","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/0333102414550416","volume":"35","author":"G Roberto","year":"2015","unstructured":"Roberto G, Raschi E, Piccinni C, Conti V, Vignatelli L, D\u2019Alessandro R et al (2015) Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. Cephalalgia 35(2):118\u2013131","journal-title":"Cephalalgia"},{"issue":"5","key":"11706_CR129","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1526-4610.2004.04078.x","volume":"44","author":"D Dodick","year":"2004","unstructured":"Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, MaassenVanDenBrink A et al (2004) Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 44(5):414\u2013425","journal-title":"Headache"},{"issue":"10","key":"11706_CR130","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1177\/0333102410370873","volume":"30","author":"DL Nelson","year":"2010","unstructured":"Nelson DL, Phebus LA, Johnson KW, Wainscott DB, Cohen ML, Calligaro DO et al (2010) Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 30(10):1159\u20131169","journal-title":"Cephalalgia"},{"issue":"3","key":"11706_CR131","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/bph.15699","volume":"179","author":"M Vila-Pueyo","year":"2022","unstructured":"Vila-Pueyo M, Page K, Murdock PR, Loraine HJ, Woodrooffe AJ, Johnson KW et al (2022) The selective 5-HT(1F) receptor agonist lasmiditan inhibits trigeminal nociceptive processing: implications for migraine and cluster headache. Br J Pharmacol 179(3):358\u2013370","journal-title":"Br J Pharmacol"},{"issue":"10","key":"11706_CR132","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1177\/0333102410375512","volume":"30","author":"MD Ferrari","year":"2010","unstructured":"Ferrari MD, F\u00e4rkkil\u00e4 M, Reuter U, Pilgrim A, Davis C, Krauss M et al (2010) Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan\u2014a randomised proof-of-concept trial. Cephalalgia Int J Headache 30(10):1170\u20131178","journal-title":"Cephalalgia Int J Headache"},{"issue":"5","key":"11706_CR133","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1474-4422(12)70047-9","volume":"11","author":"M F\u00e4rkkil\u00e4","year":"2012","unstructured":"F\u00e4rkkil\u00e4 M, Diener H-C, G\u00e9raud G, L\u00e1inez M, Schoenen J, Harner N et al (2012) Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 11(5):405\u2013413","journal-title":"Lancet Neurol"},{"issue":"24","key":"11706_CR134","doi-asserted-by":"publisher","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","volume":"91","author":"B Kuca","year":"2018","unstructured":"Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB (2018) Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology 91(24):e2222\u2013e2232","journal-title":"Neurology"},{"issue":"7","key":"11706_CR135","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/brain\/awz134","volume":"142","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK et al (2019) Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain J Neurol 142(7):1894\u20131904","journal-title":"Brain J Neurol"},{"issue":"3","key":"11706_CR136","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/0333102421989232","volume":"41","author":"M Ashina","year":"2021","unstructured":"Ashina M, Reuter U, Smith T, Krikke-Workel J, Klise SR, Bragg S et al (2021) Randomized, controlled trial of lasmiditan over four migraine attacks: findings from the CENTURION study. Cephalalgia Int J Headache 41(3):294\u2013304","journal-title":"Cephalalgia Int J Headache"},{"issue":"1","key":"11706_CR137","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s10194-019-1044-6","volume":"20","author":"RE Shapiro","year":"2019","unstructured":"Shapiro RE, Hochstetler HM, Dennehy EB, Khanna R, Doty EG, Berg PH et al (2019) Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials. J Headache Pain 20(1):90","journal-title":"J Headache Pain"},{"issue":"3","key":"11706_CR138","doi-asserted-by":"publisher","first-page":"0333","DOI":"10.1177\/03331024231151419","volume":"43","author":"F Puledda","year":"2023","unstructured":"Puledda F, Younis S, Huessler E-M, Haghdoost F, Lisicki M, Goadsby PJ et al (2023) Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: a systematic review and network meta-analysis of the literature. Cephalalgia Int J Headache 43(3):0333","journal-title":"Cephalalgia Int J Headache"},{"issue":"9656","key":"11706_CR139","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(08)61626-8","volume":"372","author":"TW Ho","year":"2008","unstructured":"Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X et al (2008) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372(9656):2115\u20132123","journal-title":"Lancet"},{"issue":"6","key":"11706_CR140","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1177\/0333102411398399","volume":"31","author":"DJ Hewitt","year":"2011","unstructured":"Hewitt DJ, Aurora SK, Dodick DW, Goadsby PJ, Ge YJ, Bachman R et al (2011) Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia Int J Headache 31(6):712\u2013722","journal-title":"Cephalalgia Int J Headache"},{"issue":"11","key":"11706_CR141","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1056\/NEJMoa030505","volume":"350","author":"J Olesen","year":"2004","unstructured":"Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U et al (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350(11):1104\u20131110","journal-title":"N Engl J Med"},{"issue":"5","key":"11706_CR142","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/0333102410388435","volume":"31","author":"HC Diener","year":"2011","unstructured":"Diener HC, Barbanti P, Dahlof C, Reuter U, Habeck J, Podhorna J (2011) BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 31(5):573\u2013584","journal-title":"Cephalalgia"},{"key":"11706_CR143","unstructured":"Food and Drug Administration (2020). Drug Approval Package: NURTEC ODT. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/212728Orig1s000TOC.cfm. Accessed 13 Mar 2022"},{"key":"11706_CR144","unstructured":"Food and Drug Administration (2019) FDA approves new treatment for adults with migraine. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-adults-migraine. Accessed 13 Mar 2022"},{"issue":"23","key":"11706_CR145","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","volume":"381","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM et al (2019) Ubrogepant for the treatment of migraine. N Engl J Med 381(23):2230\u20132241","journal-title":"N Engl J Med"},{"issue":"19","key":"11706_CR146","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.2019.16711","volume":"322","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A et al (2019) Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA 322(19):1887\u20131898","journal-title":"JAMA"},{"key":"11706_CR147","unstructured":"Lipton R, Coric V, Stock E, Stock D, Morris B, McCormack T, et al (2018). Rimegepant 75 mg, an oral calcitonin gene-related peptide antagonist, for the acute treatment of migraine: two phase 3, double-blind, randomized, placebo-controlled trials. Cephalalgia Int J Headache"},{"issue":"2","key":"11706_CR148","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M et al (2019) Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med 381(2):142\u2013149","journal-title":"N Engl J Med"},{"issue":"10200","key":"11706_CR149","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG et al (2019) Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 394(10200):737\u2013745","journal-title":"Lancet"},{"issue":"9","key":"11706_CR150","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/head.14389","volume":"62","author":"R Croop","year":"2022","unstructured":"Croop R, Madonia J, Stock DA, Thiry A, Forshaw M, Murphy A et al (2022) Zavegepant nasal spray for the acute treatment of migraine: a Phase 2\/3 double-blind, randomized, placebo-controlled, dose-ranging trial. Headache 62(9):1153\u20131163","journal-title":"Headache"},{"issue":"6","key":"11706_CR151","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.3390\/jcm11061656","volume":"11","author":"D Moreno-Ajona","year":"2022","unstructured":"Moreno-Ajona D, Villar-Martinez MD, Goadsby PJ (2022) New generation gepants: migraine acute and preventive medications. J Clin Med 11(6):1656","journal-title":"J Clin Med"},{"issue":"1","key":"11706_CR152","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40120-021-00234-7","volume":"10","author":"S Hutchinson","year":"2021","unstructured":"Hutchinson S, Dodick DW, Treppendahl C, Bennett NL, Yu SY, Guo H et al (2021) Ubrogepant for the acute treatment of migraine: pooled efficacy, safety, and tolerability from the ACHIEVE I and ACHIEVE II phase 3 randomized trials. Neurol Ther 10(1):235\u2013249","journal-title":"Neurol Ther"},{"issue":"3","key":"11706_CR153","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00409-9","volume":"21","author":"L Al-Hassany","year":"2022","unstructured":"Al-Hassany L, Goadsby PJ, Danser AHJ, MaassenVanDenBrink A (2022) Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions. Lancet Neurol 21(3):284\u2013294","journal-title":"Lancet Neurol"},{"issue":"7","key":"11706_CR154","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/j.1468-2982.2004.00723.x","volume":"24","author":"CN Sang","year":"2004","unstructured":"Sang CN, Ramadan NM, Wallihan RG, Chappell AS, Freitag FG, Smith TR et al (2004) LY293558, a novel AMPA\/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 24(7):596\u2013602","journal-title":"Cephalalgia"},{"issue":"8","key":"11706_CR155","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/acn3.302","volume":"3","author":"MW Waung","year":"2016","unstructured":"Waung MW, Akerman S, Wakefield M, Keywood C, Goadsby PJ (2016) Metabotropic glutamate receptor 5: a target for migraine therapy. Ann Clin Transl Neurol 3(8):560\u2013571","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"11706_CR156","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/0333102413499648","volume":"34","author":"B Gomez-Mancilla","year":"2014","unstructured":"Gomez-Mancilla B, Brand R, Jurgens TP, Gobel H, Sommer C, Straube A et al (2014) Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks. Cephalalgia 34(2):103\u2013113","journal-title":"Cephalalgia"},{"issue":"3","key":"11706_CR157","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/ana.23996","volume":"74","author":"PJ Goadsby","year":"2013","unstructured":"Goadsby PJ (2013) Therapeutic prospects for migraine: can paradise be regained? Ann Neurol 74(3):423\u2013434","journal-title":"Ann Neurol"},{"issue":"7","key":"11706_CR158","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1212\/WNL.0b013e3182824e66","volume":"80","author":"SK Afridi","year":"2013","unstructured":"Afridi SK, Giffin NJ, Kaube H, Goadsby PJ (2013) A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology 80(7):642\u2013647","journal-title":"Neurology"},{"issue":"8","key":"11706_CR159","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S, Diener H-C, Mitsikostas DD, Sinclair AJ et al (2021) Diagnosis and management of migraine in ten steps. Nat Rev Neurol 17(8):501\u2013514","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"11706_CR160","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/S1474-4422(15)00198-2","volume":"14","author":"HC Diener","year":"2015","unstructured":"Diener HC, Charles A, Goadsby PJ, Holle D (2015) New therapeutic approaches for the prevention and treatment of migraine. Lancet Neurol 14(10):1010\u20131022","journal-title":"Lancet Neurol"},{"issue":"1","key":"11706_CR161","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"HS American","year":"2019","unstructured":"American HS (2019) The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache 59(1):1\u201318","journal-title":"Headache"},{"issue":"22","key":"11706_CR162","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F et al (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377(22):2123\u20132132","journal-title":"N Engl J Med"},{"issue":"10161","key":"11706_CR163","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD et al (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392(10161):2280\u20132287","journal-title":"Lancet"},{"issue":"6","key":"11706_CR164","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V et al (2018) ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia Int J Headache 38(6):1026\u20131037","journal-title":"Cephalalgia Int J Headache"},{"issue":"22","key":"11706_CR165","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113\u20132122","journal-title":"N Engl J Med"},{"issue":"10203","key":"11706_CR166","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R et al (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet (London, England) 394(10203):1030\u20131040","journal-title":"Lancet (London, England)"},{"issue":"19","key":"11706_CR167","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319(19):1999\u20132008","journal-title":"JAMA"},{"issue":"24","key":"11706_CR168","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK (2018) Galcanezumab in chronic migraine. The randomized, double-blind, placebo-controlled REGAIN study. Neurology 91(24):e2211\u2013e2221","journal-title":"Neurology"},{"issue":"9","key":"11706_CR169","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR (2018) Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 75(9):1080\u20131088","journal-title":"JAMA Neurol"},{"issue":"8","key":"11706_CR170","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia Int J Headache 38(8):1442\u20131454","journal-title":"Cephalalgia Int J Headache"},{"issue":"3","key":"11706_CR171","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J et al (2020) Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia Int J Headache 40(3):241\u2013254","journal-title":"Cephalalgia Int J Headache"},{"issue":"13","key":"11706_CR172","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J et al (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94(13):e1365\u2013e1377","journal-title":"Neurology"},{"issue":"10","key":"11706_CR173","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, Kim B-K, L\u00e1inez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S et al (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 19(10):814\u2013825","journal-title":"Lancet Neurol"},{"issue":"7","key":"11706_CR174","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","volume":"21","author":"M Ashina","year":"2022","unstructured":"Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK et al (2022) Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 21(7):597\u2013607","journal-title":"Lancet Neurol"},{"issue":"3","key":"11706_CR175","first-page":"0331","volume":"43","author":"F Haghdoost","year":"2023","unstructured":"Haghdoost F, Puledda F, Huessler EM, Messina R, Pozo-Rosich P (2023) Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia Int J Headache 43(3):0331","journal-title":"Cephalalgia Int J Headache"},{"issue":"3","key":"11706_CR176","doi-asserted-by":"publisher","first-page":"0331","DOI":"10.1177\/03331024231152169","volume":"43","author":"R Messina","year":"2023","unstructured":"Messina R, Huessler EM, Puledda F, Haghdoost F, Lebedeva ER, Diener HC (2023) Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and meta-analysis. Cephalalgia Int J Headache 43(3):0331","journal-title":"Cephalalgia Int J Headache"},{"issue":"1","key":"11706_CR177","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s10194-021-01363-y","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri F, Brunelli N, Messina R, Costa CM, Colombo B, Torelli P et al (2021) Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. J Headache Pain 22(1):154","journal-title":"J Headache Pain"},{"issue":"7","key":"11706_CR178","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2662","volume":"12","author":"M Nsaka","year":"2022","unstructured":"Nsaka M, Scheffler A, Wurthmann S, Schenk H, Kleinschnitz C, Glas M et al (2022) Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies. Brain Behav 12(7):e2662","journal-title":"Brain Behav"},{"issue":"6","key":"11706_CR179","first-page":"e834","volume":"11","author":"FS di Cola","year":"2021","unstructured":"di Cola FS, Caratozzolo S, Venturelli E, Balducci U, Sidoti V, Pari E et al (2021) Erenumab discontinuation after 12-month treatment: a multicentric, observational real-life study. Neurol Clin Pract 11(6):e834\u2013e900","journal-title":"Neurol Clin Pract"},{"issue":"1","key":"11706_CR180","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s10194-021-01368-7","volume":"22","author":"M Terhart","year":"2021","unstructured":"Terhart M, Mecklenburg J, Neeb L, Overeem LH, Siebert A, Steinicke M et al (2021) Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(-receptor) antibodies. J Headache Pain 22(1):158","journal-title":"J Headache Pain"},{"issue":"1","key":"11706_CR181","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u20142022 update. J Headache Pain 23(1):67","journal-title":"J Headache Pain"},{"issue":"8","key":"11706_CR182","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","volume":"385","author":"J Ailani","year":"2021","unstructured":"Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L et al (2021) Atogepant for the preventive treatment of migraine. N Engl J Med 385(8):695\u2013706","journal-title":"N Engl J Med"},{"issue":"9","key":"11706_CR183","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1474-4422(20)30234-9","volume":"19","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K et al (2020) Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b\/3 trial. Lancet Neurol 19(9):727\u2013737","journal-title":"Lancet Neurol"},{"issue":"10268","key":"11706_CR184","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM et al (2021) Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet (London, England) 397(10268):51\u201360","journal-title":"Lancet (London, England)"},{"issue":"7","key":"11706_CR185","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/cpdd.916","volume":"10","author":"R Boinpally","year":"2021","unstructured":"Boinpally R, Jakate A, Butler M, Borbridge L, Periclou A (2021) Single-dose pharmacokinetics and safety of atogepant in adults with hepatic impairment: results from an open-label, phase 1 trial. Clin Pharmacol Drug Dev 10(7):726\u2013733","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"Suppl 1","key":"11706_CR186","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/1129-2377-14-S1-P118","volume":"14","author":"G Tong","year":"2013","unstructured":"Tong G, Savant I, Jariwala N, Burt D, Zheng N, Buzescu A et al (2013) Phase I single and multiple dose study to evaluate the safety, tolerability. J Headache Pain 14(Suppl 1):118","journal-title":"J Headache Pain"},{"key":"11706_CR187","unstructured":"AbbVie. (2021) QULIPTA (atogepant) tablets, for oral use: US prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215206Orig1s000lbl.pdf. Accessed 13 Mar 2022"},{"issue":"2","key":"11706_CR188","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/cts.12917","volume":"14","author":"KC Min","year":"2021","unstructured":"Min KC, Kraft WK, Bondiskey P, Col\u00f3n-Gonz\u00e1lez F, Liu W, Xu J et al (2021) Atogepant is not associated with clinically meaningful alanine aminotransferase elevations in healthy adults. Clin Transl Sci 14(2):599\u2013605","journal-title":"Clin Transl Sci"},{"issue":"9","key":"11706_CR189","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/cpdd.940","volume":"10","author":"R Boinpally","year":"2021","unstructured":"Boinpally R, McNamee B, Yao L, Butler M, McGeeney D, Borbridge L et al (2021) A single supratherapeutic dose of atogepant does not affect cardiac repolarization in healthy adults: results from a randomized, single-dose, phase 1 crossover trial. Clin Pharmacol Drug Dev 10(9):1099\u20131107","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1S","key":"11706_CR190","first-page":"14","volume":"42","author":"P Pozo-Rosich","year":"2022","unstructured":"Pozo-Rosich P, Ailani J, Ashina M, Goadsby PJ, Lipton R, Reuter U et al (2022) Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial. Cephalalgia Int J Headache 42(1S):14\u201315","journal-title":"Cephalalgia Int J Headache"},{"issue":"14","key":"11706_CR191","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1177\/03331024221123058","volume":"42","author":"M Lanteri-Minet","year":"2022","unstructured":"Lanteri-Minet M, Ducros A, Francois C, Olewinska E, Nikodem M, Dupont-Benjamin L (2022) Effectiveness of onabotulinumtoxinA (BOTOX(R)) for the preventive treatment of chronic migraine: a meta-analysis on 10 years of real-world data. Cephalalgia 42(14):1543\u20131564","journal-title":"Cephalalgia"},{"issue":"1","key":"11706_CR192","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15360288.2020.1829249","volume":"35","author":"M Armanious","year":"2021","unstructured":"Armanious M, Khalil N, Lu Y, Jimenez-Sanders R (2021) Erenumab and OnabotulinumtoxinA combination therapy for the prevention of intractable chronic migraine without aura: a retrospective analysis. J Pain Palliat Care Pharmacother 35(1):1\u20136","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"8","key":"11706_CR193","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3390\/toxins14080529","volume":"14","author":"D Scuteri","year":"2022","unstructured":"Scuteri D, Tonin P, Nicotera P, Vulnera M, Altieri GC, Tarsitano A et al (2022) Pooled analysis of real-world evidence supports anti-CGRP mAbs and OnabotulinumtoxinA combined trial in chronic migraine. Toxins (Basel). 14(8):529","journal-title":"Toxins (Basel)."},{"issue":"8","key":"11706_CR194","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1093\/pm\/pnab093","volume":"22","author":"F Cohen","year":"2021","unstructured":"Cohen F, Armand C, Lipton RB, Vollbracht S (2021) Efficacy and tolerability of calcitonin gene-related peptide-targeted monoclonal antibody medications as add-on therapy to OnabotulinumtoxinA in patients with chronic migraine. Pain Med 22(8):1857\u20131863","journal-title":"Pain Med"},{"issue":"4\u20135","key":"11706_CR195","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1177\/03331024211047454","volume":"42","author":"D Chowdhury","year":"2022","unstructured":"Chowdhury D, Bansal L, Duggal A, Datta D, Mundra A, Krishnan A et al (2022) TOP-PRO study: a randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine. Cephalalgia 42(4\u20135):396\u2013408","journal-title":"Cephalalgia"},{"issue":"4","key":"11706_CR196","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/ane.12626","volume":"135","author":"KL Lai","year":"2017","unstructured":"Lai KL, Niddam DM, Fuh JL, Chen SP, Wang YF, Chen WT et al (2017) Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial. Acta Neurol Scand 135(4):476\u2013483","journal-title":"Acta Neurol Scand"},{"issue":"11","key":"11706_CR197","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1007\/s00415-020-09989-9","volume":"267","author":"R Messina","year":"2020","unstructured":"Messina R, Lastarria Perez CP, Filippi M, Goadsby PJ (2020) Candesartan in migraine prevention: results from a retrospective real-world study. J Neurol 267(11):3243\u20133247","journal-title":"J Neurol"},{"issue":"1","key":"11706_CR198","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1038\/s41598-021-83508-2","volume":"11","author":"C Sanchez-Rodriguez","year":"2021","unstructured":"Sanchez-Rodriguez C, Sierra A, Planchuelo-Gomez A, Martinez-Pias E, Guerrero AL, Garcia-Azorin D (2021) Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study. Sci Rep 11(1):3846","journal-title":"Sci Rep"},{"issue":"7","key":"11706_CR199","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1111\/head.13828","volume":"60","author":"I Liampas","year":"2020","unstructured":"Liampas I, Siokas V, Brotis A, Vikelis M, Dardiotis E (2020) Endogenous melatonin levels and therapeutic use of exogenous melatonin in migraine: systematic review and meta-analysis. Headache 60(7):1273\u20131299","journal-title":"Headache"},{"issue":"2","key":"11706_CR200","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.12663","volume":"69","author":"PT Tseng","year":"2020","unstructured":"Tseng PT, Yang CP, Su KP, Chen TY, Wu YC, Tu YK et al (2020) The association between melatonin and episodic migraine: a pilot network meta-analysis of randomized controlled trials to compare the prophylactic effects with exogenous melatonin supplementation and pharmacotherapy. J Pineal Res 69(2):e12663","journal-title":"J Pineal Res"},{"issue":"3","key":"11706_CR201","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/WNF.0000000000000504","volume":"45","author":"T Zhou","year":"2022","unstructured":"Zhou T, Tang Y, Zhu H (2022) Effectiveness and safety of memantine for headache: a meta-analysis of randomized controlled studies. Clin Neuropharmacol 45(3):40\u201344","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"11706_CR202","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/head.13069","volume":"57","author":"F Puledda","year":"2017","unstructured":"Puledda F, Goadsby PJ (2017) An update on non-pharmacological neuromodulation for the acute and preventive treatment of migraine. Headache 57(4):685\u2013691","journal-title":"Headache"},{"issue":"4","key":"11706_CR203","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1474-4422(10)70054-5","volume":"9","author":"RB Lipton","year":"2010","unstructured":"Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Pearlman SH et al (2010) Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol 9(4):373\u2013380","journal-title":"Lancet Neurol"},{"key":"11706_CR204","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1186\/s10194-015-0535-3","volume":"16","author":"R Bhola","year":"2015","unstructured":"Bhola R, Kinsella E, Giffin N, Lipscombe S, Ahmed F, Weatherall M et al (2015) Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program. J Headache Pain 16:535","journal-title":"J Headache Pain"},{"issue":"6","key":"11706_CR205","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1177\/0333102418762525","volume":"38","author":"AJ Starling","year":"2018","unstructured":"Starling AJ, Tepper SJ, Marmura MJ, Shamim EA, Robbins MS, Hindiyeh N et al (2018) A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia Int J Head 38(6):1038\u20131048","journal-title":"Cephalalgia Int J Head"},{"issue":"1","key":"11706_CR206","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s10194-022-01428-6","volume":"23","author":"JO Lloyd","year":"2022","unstructured":"Lloyd JO, Hill B, Murphy M, Al-Kaisy A, Andreou AP, Lambru G (2022) Single-pulse transcranial magnetic stimulation for the preventive treatment of difficult-to-treat migraine: a 12-month prospective analysis. J Headache Pain 23(1):63","journal-title":"J Headache Pain"},{"issue":"1","key":"11706_CR207","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0333102418811573","volume":"39","author":"DE Chou","year":"2019","unstructured":"Chou DE, Shnayderman Yugrakh M, Winegarner D, Rowe V, Kuruvilla D, Schoenen J (2019) Acute migraine therapy with external trigeminal neurostimulation (ACME): a randomized controlled trial. Cephalalgia Int J Headache 39(1):3\u201314","journal-title":"Cephalalgia Int J Headache"},{"issue":"8","key":"11706_CR208","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1212\/WNL.0b013e3182825055","volume":"80","author":"J Schoenen","year":"2013","unstructured":"Schoenen J, Vandersmissen B, Jeangette S, Herroelen L, Vandenheede M, Gerard P et al (2013) Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology 80(8):697\u2013704","journal-title":"Neurology"},{"issue":"1","key":"11706_CR209","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12883-017-0869-3","volume":"17","author":"M Vikelis","year":"2017","unstructured":"Vikelis M, Dermitzakis EV, Spingos KC, Vasiliadis GG, Vlachos GS, Kararizou E (2017) Clinical experience with transcutaneous supraorbital nerve stimulation in patients with refractory migraine or with migraine and intolerance to topiramate: a prospective exploratory clinical study. BMC Neurol 17(1):97","journal-title":"BMC Neurol"},{"issue":"2","key":"11706_CR210","first-page":"415","volume":"21","author":"CM Ordas","year":"2020","unstructured":"Ordas CM, Cuadrado ML, Pareja JA, de-Las-Casas-Camara G, Gomez-Vicente L, Torres-Gaona G et al (2020) Transcutaneous supraorbital stimulation as a preventive treatment for chronic migraine: a prospective, open-label study. Pain Med 21(2):415\u2013422","journal-title":"Pain Med"},{"issue":"4","key":"11706_CR211","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1212\/WNL.0000000000005857","volume":"91","author":"C Tassorelli","year":"2018","unstructured":"Tassorelli C, Grazzi L, de Tommaso M, Pierangeli G, Martelletti P, Rainero I et al (2018) Noninvasive vagus nerve stimulation as acute therapy for migraine: the randomized PRESTO study. Neurology 91(4):e364\u2013e373","journal-title":"Neurology"},{"issue":"12","key":"11706_CR212","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1177\/0333102419876920","volume":"39","author":"HC Diener","year":"2019","unstructured":"Diener HC, Goadsby PJ, Ashina M, Al-Karagholi MA, Sinclair A, Mitsikostas D et al (2019) Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: the multicentre, double-blind, randomised, sham-controlled PREMIUM trial. Cephalalgia 39(12):1475\u20131487","journal-title":"Cephalalgia"},{"issue":"5","key":"11706_CR213","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1212\/WNL.0000000000002918","volume":"87","author":"SD Silberstein","year":"2016","unstructured":"Silberstein SD, Calhoun AH, Lipton RB, Grosberg BM, Cady RK, Dorlas S et al (2016) Chronic migraine headache prevention with noninvasive vagus nerve stimulation: the EVENT study. Neurology 87(5):529\u2013538","journal-title":"Neurology"},{"issue":"7","key":"11706_CR214","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1177\/03331024211068813","volume":"42","author":"U Najib","year":"2022","unstructured":"Najib U, Smith T, Hindiyeh N, Saper J, Nye B, Ashina S et al (2022) Non-invasive vagus nerve stimulation for prevention of migraine: the multicenter, randomized, double-blind, sham-controlled PREMIUM II trial. Cephalalgia Int J Headache 42(7):560\u2013569","journal-title":"Cephalalgia Int J Headache"},{"issue":"4","key":"11706_CR215","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1097\/j.pain.0000000000000437","volume":"157","author":"SP Chen","year":"2016","unstructured":"Chen SP, Ay I, de Morais AL, Qin T, Zheng Y, Sadeghian H et al (2016) Vagus nerve stimulation inhibits cortical spreading depression. Pain 157(4):797\u2013805","journal-title":"Pain"},{"key":"11706_CR216","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.nbd.2017.03.004","volume":"102","author":"S Akerman","year":"2017","unstructured":"Akerman S, Simon B, Romero-Reyes M (2017) Vagus nerve stimulation suppresses acute noxious activation of trigeminocervical neurons in animal models of primary headache. Neurobiol Dis 102:96\u2013104","journal-title":"Neurobiol Dis"},{"issue":"7","key":"11706_CR217","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1177\/0333102411399349","volume":"31","author":"A Antal","year":"2011","unstructured":"Antal A, Kriener N, Lang N, Boros K, Paulus W (2011) Cathodal transcranial direct current stimulation of the visual cortex in the prophylactic treatment of migraine. Cephalalgia Int J Headache 31(7):820\u2013828","journal-title":"Cephalalgia Int J Headache"},{"key":"11706_CR218","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1129-2377-14-23","volume":"14","author":"A Vigano","year":"2013","unstructured":"Vigano A, D\u2019Elia TS, Sava SL, Auve M, De Pasqua V, Colosimo A et al (2013) Transcranial direct current stimulation (tDCS) of the visual cortex: a proof-of-concept study based on interictal electrophysiological abnormalities in migraine. J Headache Pain 14:23","journal-title":"J Headache Pain"},{"key":"11706_CR219","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3389\/fphar.2019.00032","volume":"10","author":"A Vigan\u00f2","year":"2019","unstructured":"Vigan\u00f2 A, Toscano M, Puledda F, Di Piero V (2019) Treating chronic migraine with neuromodulation: the role of neurophysiological abnormalities and maladaptive plasticity. Front Pharmacol 10:32","journal-title":"Front Pharmacol"},{"issue":"2","key":"11706_CR220","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/SPC.0000000000000126","volume":"9","author":"RR Nir","year":"2015","unstructured":"Nir RR, Yarnitsky D (2015) Conditioned pain modulation. Curr Opin Support Palliat Care 9(2):131\u2013137","journal-title":"Curr Opin Support Palliat Care"},{"issue":"8","key":"11706_CR221","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1111\/head.13551","volume":"59","author":"D Yarnitsky","year":"2019","unstructured":"Yarnitsky D, Dodick DW, Grosberg BM, Burstein R, Ironi A, Harris D et al (2019) Remote electrical neuromodulation (REN) relieves acute migraine: a randomized, double-blind, placebo-controlled, multicenter trial. Headache 59(8):1240\u20131252","journal-title":"Headache"},{"issue":"2","key":"11706_CR222","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s40122-020-00185-1","volume":"9","author":"H Nierenburg","year":"2020","unstructured":"Nierenburg H, Vieira JR, Lev N, Lin T, Harris D, Vizel M et al (2020) Remote electrical neuromodulation for the acute treatment of migraine in patients with chronic migraine: an open-label pilot study. Pain Ther 9(2):531\u2013543","journal-title":"Pain Ther"},{"key":"11706_CR223","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3389\/fneur.2019.00738","volume":"10","author":"T Renner","year":"2019","unstructured":"Renner T, Sollmann N, Trepte-Freisleder F, Albers L, Mathonia NM, Bonfert MV et al (2019) Repetitive peripheral magnetic stimulation (rPMS) in subjects with migraine-setup presentation and effects on skeletal musculature. Front Neurol 10:738","journal-title":"Front Neurol"},{"key":"11706_CR224","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.919623","volume":"13","author":"C Borner","year":"2022","unstructured":"Borner C, Renner T, Trepte-Freisleder F, Urban G, Schandelmaier P, Lang M et al (2022) Response predictors of repetitive neuromuscular magnetic stimulation in the preventive treatment of episodic migraine. Front Neurol 13:919623","journal-title":"Front Neurol"},{"issue":"8","key":"11706_CR225","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/head.14350","volume":"62","author":"SJ Tepper","year":"2022","unstructured":"Tepper SJ, Grosberg B, Daniel O, Kuruvilla DE, Vainstein G, Deutsch L et al (2022) Migraine treatment with external concurrent occipital and trigeminal neurostimulation-A randomized controlled trial. Headache 62(8):989\u20131001","journal-title":"Headache"},{"issue":"3","key":"11706_CR226","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s40122-022-00394-w","volume":"11","author":"O Daniel","year":"2022","unstructured":"Daniel O, Tepper SJ, Deutsch L, Sharon R (2022) External concurrent occipital and trigeminal neurostimulation relieves migraine headache: a prospective, randomized, double-blind, Sham-controlled trial. Pain Ther 11(3):907\u2013922","journal-title":"Pain Ther"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11706-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-11706-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11706-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T06:07:58Z","timestamp":1702188478000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-11706-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,8]]},"references-count":226,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["11706"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-11706-1","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,8]]},"assertion":[{"value":"13 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}